BRANDY BYRD: Open Payments
NPI 1013491992 · BRANDON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,270 in 100 payments from 13 companies in 2025. Trend: 2023 $1,398 · 2024 $1,721 · 2025 $2,270
Food & beverage: $2,059Education: $211
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 13 | $483 |
| Teva Pharmaceuticals USA, Inc. | 9 | $360 |
| Alkermes, Inc. | 12 | $190 |
| Neurocrine BioSciences, Inc. | 9 | $175 |
| ABBVIE INC. | 12 | $172 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $171 |
| E.R. Squibb & Sons, L.L.C. | 10 | $163 |
| Lundbeck LLC | 8 | $160 |
| Janssen Pharmaceuticals, Inc | 7 | $154 |
| Otsuka America Pharmaceutical, Inc. | 7 | $137 |
Products named: Auvelity, ARISTADA, INGREZZA, VRAYLAR, CAPLYTA, REXULTI, COBENFY, INVEGA SUSTENNA.
Industry payments across MS — which companies pay providers there.
